المؤلفون: Xavier Leleu, Hans C. Lee, Jeffrey A. Zonder, Margaret Macro, Karthik Ramasamy, Cyrille Hulin, Jiri Silar, Matyas Kuhn, Kaili Ren, Nawal Bent-Ennakhil, Dasha Cherepanov, Dawn Marie Stull, Evangelos Terpos

مصطلحات موضوعية: Oncology and carcinogenesis not elsewhere classified, effectiveness, ixazomib, ixazomib-lenalidomide-dexamethasone, IRd, multiple myeloma, pooled analysis, progression-free survival, proteasome inhibitor, relapsed/refractory, routine clinical practice, time-to-next treatment

العلاقة: https://figshare.com/articles/dataset/INSURE_A_pooled_analysis_of_ixazomib-lenalidomide-dexamethasone_for_relapsed_refractory_myeloma_in_routine_practice_-_supplementary_material/24972678Test

الإتاحة: https://doi.org/10.25402/fon.24972678.v1Test
https://figshare.com/articles/dataset/INSURE_A_pooled_analysis_of_ixazomib-lenalidomide-dexamethasone_for_relapsed_refractory_myeloma_in_routine_practice_-_supplementary_material/24972678Test

المؤلفون: Jeffrey A. Zonder, Alexandra Jungova, Magda Bařinová, Katja Weisel, Roman Hájek, Evangelos Terpos, Frits van Rhee, Rafat Abonour, Jorge Vela-Ojeda, Michael A. Thompson, Robert M. Rifkin, Jin Lu, Jennifer Elliott, Xavier Leleu, Vladimir Maisnar, Kenny Galvez, Ajai Chari, Faith E. Davies, Lenka Capkova, Jiří Minařík, Caitlin Costello, Lucie Brozova, Jan Straub, Jesus G. Berdeja, Noemi Puig, Hans C. Lee, Kaili Ren, Mario Boccadoro, Jiří Šilar, Saad Z. Usmani, Dawn Marie Stull, Gordon Cook, Matyáš Kuhn, Luděk Pour, Andrew Spencer, Vania Tm Hungria

المساهمون: Millennium Pharmaceuticals, Takeda Pharmaceutical Company

المصدر: Digital.CSIC. Repositorio Institucional del CSIC
instname

مصطلحات موضوعية: Adult, Boron Compounds, Male, Cancer Research, medicine.medical_specialty, Glycine, Effectiveness, Routine clinical practice, Ixazomib, Dexamethasone, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Proteasome inhibitor, Prospective Studies, Adverse effect, Lenalidomide, Aged, Aged, 80 and over, business.industry, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Monoclonal, Female, Observational study, Relapsed/refractory, Neoplasm Recurrence, Local, business, 030215 immunology, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb2eb25f28b45fad8a319815d33ed8eTest
http://hdl.handle.net/10261/261619Test